The Index of Severity for Eosinophilic Esophagitis Helps Predict Treatment Response to Dupilumab
Clinical Gastroenterology and Hepatology · 2026-07 · 24 (7) · 2024-2027.e1
DOI: 10.1016/j.cgh.2025.04.016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-07. Verfasst von Corey J Ketchem und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electron…. Hauptthemen laut MEDLINE: Eosinophilic Esophagitis, Severity of Illness Index, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIAID NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction due to eosinophilic infiltration.1 Evidence suggests a progression from inflammatory to fibrostenotic disease in many patients, but no consensus exists on how best to monitor the clinical trajectory of EoE. This has led to highly variable clinical practicez that often diverge from clinical guidelines.2 In other gastrointestinal diseases with a treat-to-target approaches, clinical tools have been developed to monitor disease activity, but analogous tools had been lacking for EoE.3,4 Recently, a scoring system was devised for clinical assessment of EoE, the Index of Severity for Eosinophilic Esophagitis (I-SEE), that divides key disease features into 3 categories: symptoms and complications, inflammatory features, and fibrostenotic features.5 Since its inception, several studies have explored the relationship between I-SEE scores and disease response, finding that I-SEE accurately gauged disease severity and treatment response.6-8 It is currently uncertain if changes in I-SEE scores are associated with response to dupilumab treatment. Therefore, the goals of our study were to determine if I-SEE scores were associated with traditional response metrics when using dupilumab therapy and whether response differences to dupilumab exist based on I-SEE categories within an EoE population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: ketchemc@pennmedicine.upenn.edu.
- Department of Medicine, Division of Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
- Department of Medicine, Division of Gastroenterology and Hepatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
- Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina; Center for Gastrointestin…
Förderung
- NIDDK NIH HHS
- NIAID NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ketchem, C. J., Dash, A., Falk, G. W., Dellon, E. S., & Lynch, K. L. (2026). The Index of Severity for Eosinophilic Esophagitis Helps Predict Treatment Response to Dupilumab. Clinical Gastroenterology and Hepatology, 24(7), 2024-2027.e1. https://doi.org/10.1016/j.cgh.2025.04.016
Vancouver
Ketchem CJ, Dash A, Falk GW, Dellon ES, Lynch KL. The Index of Severity for Eosinophilic Esophagitis Helps Predict Treatment Response to Dupilumab. Clinical Gastroenterology and Hepatology. 2026;24(7):2024-2027.e1. doi:10.1016/j.cgh.2025.04.016
BibTeX
@article{Ketchem2026,
author = {Ketchem, Corey J and Dash, Anwesh and Falk, Gary W and Dellon, Evan S and Lynch, Kristle L},
title = {The Index of Severity for Eosinophilic Esophagitis Helps Predict Treatment Response to Dupilumab},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {7},
pages = {2024--2027.e1},
doi = {10.1016/j.cgh.2025.04.016}
}
EUVIMED